002826.SZ
Tibet AIM Pharm. Inc. [002826.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002826.SZ Stock Summary
Top 10 Correlated ETFs
002826.SZ
Top 10 Correlated Stocks
002826.SZ
In the News
002826.SZ Financial details
Company Rating
Buy
Market Cap
2.29B
Income
46.78M
Revenue
803.27M
Book val./share
-
Cash/share
-
Dividend
0.1
Dividend %
0.83%
Employees
447
Optionable
No
Shortable
Yes
Earnings
28 Apr 2021
P/E
51.06
Forward P/E
-
PEG
-36.95
P/S
2.86
P/B
3.17
P/C
-
P/FCF
30.49
Quick Ratio
2.15
Current Ratio
2.4
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
0.19
EPS next Y
-
EPS next Q
-
EPS this Y
4.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.09%
Revenue last 5Y
11.88%
Revenue Q/Q
-21.04%
EPS Q/Q
-
-
-
-
-
SMA20
2.56%
SMA50
8.48%
SMA100
16.85%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
6%
ROC
0.07%
Gross Margin
47%
Oper. Margin
7%
Profit Margin
6%
Payout
44%
Shs Outstand
190.68M
Shs Float
163.58M
-
-
-
-
Target Price
-
52W Range
9.87-13.28
52W High
-7.54%
52W Low
+33.56%
RSI
44.47
Rel Volume
0.28
Avg Volume
10.23M
Volume
2.87M
Perf Week
-4.83%
Perf Month
2.04%
Perf Quarter
10.68%
Perf Half Y
7.8%
-
-
-
-
Beta
0.211
-
-
Volatility
0.24%, 0.28%
Prev Close
0.25%
Price
12.02
Change
-2.44%
002826.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.52 | 2.96 | 3.23 | 3.76 | 4.46 | |
| Net income per share | 0.13 | 0.2 | 0.22 | 0.22 | 0.23 | |
| Operating cash flow per share | 0.07 | 0.32 | 0.54 | 0.57 | 0.36 | |
| Free cash flow per share | -0.28 | -0.6 | 0.34 | 0.44 | 0.34 | |
| Cash per share | 1.23 | 1.02 | 1.1 | 0.95 | 1.67 | |
| Book value per share | 3.18 | 3.49 | 3.68 | 3.72 | 3.88 | |
| Tangible book value per share | 2.91 | 3.2 | 3.4 | 3.35 | 3.56 | |
| Share holders equity per share | 3.18 | 3.49 | 3.68 | 3.72 | 3.88 | |
| Interest debt per share | 0.21 | 0.39 | 0.22 | 0 | 0.27 | |
| Market cap | 1.94B | 1.89B | 1.82B | 2.11B | 1.96B | |
| Enterprise value | 1.74B | 1.8B | 1.66B | 1.93B | 1.68B | |
| P/E ratio | 76.73 | 50.55 | 44.36 | 49.77 | 44.3 | |
| Price to sales ratio | 3.96 | 3.41 | 3.03 | 2.91 | 2.28 | |
| POCF ratio | 145.55 | 31.87 | 17.92 | 19.3 | 28.57 | |
| PFCF ratio | -35.62 | -16.96 | 28.8 | 25.07 | 29.97 | |
| P/B Ratio | 3.13 | 2.89 | 2.65 | 2.95 | 2.62 | |
| PTB ratio | 3.13 | 2.89 | 2.65 | 2.95 | 2.62 | |
| EV to sales | 3.56 | 3.25 | 2.75 | 2.66 | 1.97 | |
| Enterprise value over EBITDA | 42.92 | 29.96 | 24.53 | 27.37 | 20.12 | |
| EV to operating cash flow | 130.63 | 30.35 | 16.29 | 17.64 | 24.6 | |
| EV to free cash flow | -31.97 | -16.15 | 26.18 | 22.9 | 25.81 | |
| Earnings yield | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Free cash flow yield | -0.03 | -0.06 | 0.03 | 0.04 | 0.03 | |
| Debt to equity | 0.06 | 0.11 | 0.06 | 0 | 0.07 | |
| Debt to assets | 0.05 | 0.08 | 0.04 | 0 | 0.05 | |
| Net debt to EBITDA | -4.9 | -1.5 | -2.45 | -2.59 | -3.24 | |
| Current ratio | 3.37 | 2.22 | 2.06 | 3.65 | 2.2 | |
| Interest coverage | 19.46 | 17.61 | 26.67 | 57.69 | 68.75 | |
| Income quality | 0.53 | 1.59 | 2.48 | 2.52 | 1.48 | |
| Dividend Yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.51 | 0.23 | 0.23 | 0.38 | 0.45 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | |
| Research and developement to revenue | 0.03 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.07 | 0.07 | 0.06 | 0.09 | 0.07 | |
| Capex to operating cash flow | -5.09 | -2.88 | -0.38 | -0.23 | -0.05 | |
| Capex to revenue | -0.14 | -0.31 | -0.06 | -0.03 | 0 | |
| Capex to depreciation | -7.15 | -15.62 | -2.3 | -1.06 | -0.14 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.05 | 3.97 | 4.27 | 4.29 | 4.48 | |
| ROIC | 0.04 | 0.05 | 0.05 | 0.06 | 0.06 | |
| Return on tangible assets | 0.04 | 0.05 | 0.05 | 0.06 | 0.05 | |
| Graham Net | 1.34 | 0.81 | 0.87 | 1.04 | 1.21 | |
| Working capital | 326.56M | 220.26M | 231.98M | 262.83M | 313.1M | |
| Tangible asset value | 564.54M | 597.56M | 635.87M | 646.39M | 682.42M | |
| Net current asset value | 324.68M | 217.33M | 229.31M | 257.81M | 306.8M | |
| Invested capital | 0.06 | 0.11 | 0.06 | 0 | 0.07 | |
| Average receivables | 189.03M | 184.44M | 198.69M | 182.9M | 174.96M | |
| Average payables | 9.69M | 19.09M | 33.08M | 28.2M | 72.11M | |
| Average inventory | 31.42M | 29.13M | 25.15M | 27.15M | 39.58M | |
| Days sales outstanding | 145.95 | 114.42 | 135.64 | 71.37 | 88.64 | |
| Days payables outstanding | 12.32 | 26.53 | 37.07 | 13.5 | 96.47 | |
| Days of inventory on hand | 31.45 | 29.13 | 19.58 | 26.38 | 34.6 | |
| Receivables turnover | 2.5 | 3.19 | 2.69 | 5.11 | 4.12 | |
| Payables turnover | 29.64 | 13.76 | 9.85 | 27.03 | 3.78 | |
| Inventory turnover | 11.61 | 12.53 | 18.64 | 13.83 | 10.55 | |
| ROE | 0.04 | 0.06 | 0.06 | 0.06 | 0.06 | |
| Capex per share | -0.35 | -0.91 | -0.21 | -0.13 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.97 | 1.38 | 0.82 | 1.06 | 0 | |
| Net income per share | 0.04 | 0.12 | 0.04 | 0.03 | 0 | |
| Operating cash flow per share | 0.04 | 0.12 | 0.04 | 0.24 | 0 | |
| Free cash flow per share | 0.04 | 0.11 | 0.04 | 0.24 | 0 | |
| Cash per share | 1.41 | 1.67 | 1.69 | 1.85 | 0 | |
| Book value per share | 3.38 | 3.88 | 3.6 | 3.95 | 0 | |
| Tangible book value per share | 3.07 | 3.56 | 3.31 | 3.64 | 0 | |
| Share holders equity per share | 3.38 | 3.88 | 3.6 | 3.95 | 0 | |
| Interest debt per share | 0.24 | 0.26 | 0.24 | 0.26 | 0 | |
| Market cap | 2.04B | 1.96B | 2.25B | 2.13B | 0 | |
| Enterprise value | 1.89B | 1.68B | 2.05B | 1.97B | -217.59M | |
| P/E ratio | 55.08 | 21.36 | 67.25 | 93.02 | 0 | |
| Price to sales ratio | 9.91 | 7.38 | 13.12 | 10.38 | 0 | |
| POCF ratio | 220.3 | 85.43 | 269 | 46.01 | 0 | |
| PFCF ratio | 227.48 | 89.19 | 276.26 | 46.33 | 0 | |
| P/B Ratio | 2.84 | 2.62 | 2.99 | 2.79 | 0 | |
| PTB ratio | 2.84 | 2.62 | 2.99 | 2.79 | 0 | |
| EV to sales | 9.18 | 6.36 | 11.94 | 9.61 | -1.34 | |
| Enterprise value over EBITDA | 156.37 | 52.29 | 220.12 | 328.95 | -16.23 | |
| EV to operating cash flow | 204.03 | 73.58 | 244.81 | 42.63 | -5.14K | |
| EV to free cash flow | 210.68 | 76.82 | 251.41 | 42.92 | 385.71 | |
| Earnings yield | 0 | 0.01 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0.01 | 0 | 0.02 | 0 | |
| Debt to equity | 0.07 | 0.07 | 0.07 | 0.07 | 0.01 | |
| Debt to assets | 0.05 | 0.05 | 0.05 | 0.05 | 0.01 | |
| Net debt to EBITDA | -12.47 | -8.42 | -21.75 | -26.14 | -16.23 | |
| Current ratio | 2.45 | 2.2 | 2.33 | 2.25 | 2.4 | |
| Interest coverage | 42.02 | 51.21 | 26.02 | 15.79 | 54.62 | |
| Income quality | 1 | 1 | 1 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.02 | 0.06 | 0.08 | 1.96 | |
| Sales general and administrative to revenue | 0.11 | -0.02 | 0.06 | 0.02 | 0.17 | |
| Research and developement to revenue | 0 | 0.04 | 0 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.07 | 0.07 | 0.07 | 0.06 | 0.06 | |
| Capex to operating cash flow | -0.03 | -0.04 | -0.03 | -0.01 | -14.33 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.82 | 3.23 | 1.8 | 1.62 | 0 | |
| ROIC | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Return on tangible assets | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Graham Net | 1.04 | 1.21 | 1.21 | 1.22 | 0 | |
| Working capital | 281.62M | 313.1M | 330.42M | 306.34M | 303.56M | |
| Tangible asset value | 653.96M | 682.42M | 692.3M | 703.21M | 695.71M | |
| Net current asset value | 277M | 306.8M | 321.3M | 297.43M | 294.86M | |
| Invested capital | 0.07 | 0.07 | 0.07 | 0.07 | 0.01 | |
| Average receivables | 141.34M | 173.34M | 194.86M | 163.02M | 155.85M | |
| Average payables | 54.81M | 95.91M | 121.75M | 123.88M | 140.06M | |
| Average inventory | 35.74M | 39.1M | 44.76M | 47.47M | 52.86M | |
| Days sales outstanding | 60.55 | 70.67 | 95.37 | 63.38 | 93.04 | |
| Days payables outstanding | 51.65 | 76.28 | 109.83 | 106.19 | 194.84 | |
| Days of inventory on hand | 26.02 | 27.36 | 41.44 | 41.24 | 71.64 | |
| Receivables turnover | 1.49 | 1.27 | 0.94 | 1.42 | 0.97 | |
| Payables turnover | 1.74 | 1.18 | 0.82 | 0.85 | 0.46 | |
| Inventory turnover | 3.46 | 3.29 | 2.17 | 2.18 | 1.26 | |
| ROE | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Capex per share | 0 | -0.01 | 0 | 0 | 0 |
002826.SZ Frequently Asked Questions
What is Tibet AIM Pharm. Inc. stock symbol ?
Tibet AIM Pharm. Inc. is a CN stock and trading under the symbol 002826.SZ
What is Tibet AIM Pharm. Inc. stock quote today ?
Tibet AIM Pharm. Inc. stock price is $12.02 today.
Is Tibet AIM Pharm. Inc. stock public?
Yes, Tibet AIM Pharm. Inc. is a publicly traded company.
Company Profile
- Volume Average 10.23M
- Market Capitalization 2.29B
- Employee 447
- CEO Mr. Ke Xu
- Headquarters Beijing,CN
- IPO Date 2016-12-12
-
Website
https://www.emyy.cn 
Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.
